Royalty Pharma (RPRX) Assets (2019 - 2026)
Royalty Pharma (RPRX) posted Assets of $19.8 billion for Q1 2026, up 0.99% sequentially from $19.6 billion in Q4 2025, and up 12.53% YoY from $17.6 billion in Q1 2025.
Royalty Pharma (RPRX) Assets (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Assets for 8 years, with the latest figure at $19.8 billion in Q1 2026.
- Quarterly Assets rose 12.53% year-over-year to $19.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 billion (up 12.53% YoY) and the FY2025 annual result came in at $19.6 billion, up 7.67% from the prior year.
- Assets rose to $19.8 billion in Q1 2026 per RPRX's latest filing, from $19.6 billion in the prior quarter.
- Over five years, Assets peaked at $19.8 billion in Q1 2026 and troughed at $15.9 billion in Q3 2023.
- A 5-year average of $17.7 billion and a median of $17.7 billion in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2023 and 2024: Assets retreated 10.28% in 2023, then increased 13.79% in 2024.
- Over 5 years, Assets stood at $16.8 billion in 2022, then declined by 2.57% to $16.4 billion in 2023, then advanced by 11.24% to $18.2 billion in 2024, then increased by 7.67% to $19.6 billion in 2025, then climbed by 0.99% to $19.8 billion in 2026.
- According to Business Quant data, Assets over the past three periods registered $19.8 billion, $19.6 billion, and $19.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.82 Bn |
| Mar 31, 2026 | 19.82 Bn |
| Dec 31, 2025 | 19.62 Bn |
| Sep 30, 2025 | 19.35 Bn |
| Jun 30, 2025 | 18.32 Bn |
| Mar 31, 2025 | 17.61 Bn |
| Dec 31, 2024 | 18.22 Bn |
| Sep 30, 2024 | 18.04 Bn |
| Jun 30, 2024 | 17.66 Bn |
| Mar 31, 2024 | 16.13 Bn |
| Dec 31, 2023 | 16.38 Bn |
| Sep 30, 2023 | 15.86 Bn |
| Jun 30, 2023 | 17.12 Bn |
| Mar 31, 2023 | 17.07 Bn |
| Dec 31, 2022 | 16.81 Bn |
| Sep 30, 2022 | 17.67 Bn |
| Jun 30, 2022 | 17.74 Bn |
| Mar 31, 2022 | 17.38 Bn |
| Dec 31, 2021 | 17.52 Bn |
| Sep 30, 2021 | 17.73 Bn |